Safety of bivalent human papillomavirus vaccine in the US vaccine adverse event reporting system (VAERS), 2009–2017

Aims Human papillomavirus (HPV) vaccines prevent infection with oncogenic virus types. We analysed reports to the US Vaccine Adverse Event Reporting System (VAERS) of adverse events (AE) following bivalent HPV vaccine (2vHPV). Methods We conducted descriptive analysis of 2vHPV reports, reviewed indi...

Full description

Saved in:

Bibliographic Details
Published in:	British journal of clinical pharmacology 2018-12, Vol.84 (12), p.2928-2932
Main Authors:	Suragh, Tiffany A., Lewis, Paige, Arana, Jorge, Mba‐Jonas, Adamma, Li, Rongxia, Stewart, Brock, Shimabukuro, Tom T., Cano, Maria
Format:	Article
Language:	eng
Subjects:	Adolescent Adult Adverse Drug Reaction Reporting Systems Bayes Theorem bivalent human papillomavirus vaccine (2vHPV) Child Female Humans immunization Male Papillomavirus Vaccines - adverse effects Short Report Short Reports Time Factors United States vaccination vaccine adverse event reporting system (VAERS) vaccine safety Young Adult
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Aims Human papillomavirus (HPV) vaccines prevent infection with oncogenic virus types. We analysed reports to the US Vaccine Adverse Event Reporting System (VAERS) of adverse events (AE) following bivalent HPV vaccine (2vHPV). Methods We conducted descriptive analysis of 2vHPV reports, reviewed individual reports, calculated crude AE reporting rates and conducted empirical Bayesian data mining. Results Of 241 2vHPV reports, 158 were in females, 64 in males (2vHPV is approved for females only) and 19 with unknown sex; 95.8% were classified as nonserious. Dizziness, headache, nausea and injection site reactions were the most common symptoms. Crude AE reporting rates were 33.3 reports per 100 000 doses distributed overall, and 1.4 per 100 000 for serious reports. Empirical Bayesian data mining identified disproportional reporting for three types of medical errors; assessment indicated findings that were probably driven by inadvertent 2vHPV use in males. Conclusions We did not identify any new or unexpected safety concerns in our review of 2vHPV reports to VAERS.
ISSN:	0306-5251 1365-2125